

July 31, 2024

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

BSE Scrip Code: 524743

Dear Sir,

Reg : Press Release - Fischer Medical Ventures Ltd Partners with Bio Angle Vacs Sdn Bhd's in Science, Technology and Marketing to bring their Breakthrough Vaccine Products that Substantially Reduce Mortality Rate of Livestock and Aquaculture into India.

We enclose a Press Release regarding "**Fischer Medical Ventures Ltd Partners with Bio Angle Vacs Sdn Bhd's in Science, Technology and Marketing to bring their Breakthrough Vaccine Products that Substantially Reduce Mortality Rate of Livestock and Aquaculture into India**", for dissemination.

Thanking you,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN
CHAIRMAN & MANAGING DIRECTOR



Fischer
Medical Ventures Ltd
Fischer Medical Ventures Limited
(Formerly known as Fischer Chemic Ltd)
CIN L24231MH1993PLC288371

Corporate Office : Level 5, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006

Registered Office : 104, First Floor Raghuleela Mega Mall, Behind Poisar Depot, Kandivali West Mumbai, Maharashtra,

Fischer Medical Ventures Ltd Partners with Bio Angle Vacs Sdn Bhd's in Science, Technology and Marketing to bring their Breakthrough Vaccine Products that Substantially Reduce Mortality Rate of Livestock and Aquaculture into India

Fischer Medical Ventures Ltd (Fischer MV), a pioneering force in the healthcare industry, confirmed its investment and collaboration with Bio Angle Vacs Sdn Bhd (BAV), a leading Biotechnology company in Malaysia that develops, manufactures and distributes vaccines to small and large-scale farming owners worldwide; focusing on health and disease prevention for livestock and aquaculture.

Founded in 2013, BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy. Its flagship innovation, the Spray Technology Vaccine (STVAC) leverages advanced recombinant technology and intranasal administration to elicit both mucosal and systemic immune responses, demonstrating enhanced protection for small ruminants, especially goats and sheep, against bacterial infections with high mortality rates.

***Pneumonic Pasteurellosis* (pneumonia) commonly affects 30% - 60% of global goat and sheep populations can be effectively managed through vaccination, however traditional injectable vaccines requiring vet to administer are costly, time-consuming, labour-intensive and stressful for animals. In contrast, BAV's STVAC intranasal spray method minimizes stress for animals, reduces costs and simplifies the vaccination process by any handlers, hence more accessible for farmers. STVAC is tested to enhance protection of goats and sheep from pneumonia, reducing mortality rates significantly to below 5%.**



- **BAV have to date secured a total of USD 83 million annual sales contracts from China, Nigeria, Kenya, Chad, Uganda, Uzbekistan and Indonesia for its range of innovative, sought-after animal vaccines.**
- **Fischer MV (formerly known as Fischer Chemic Ltd) is known for its affordable and high quality medical diagnostic and imaging technologies, by leveraging cutting-edge innovations and AI-powered software solutions in healthcare. As the first company to indigenously manufacture advanced Magnetic Resonance Imaging (MRI) systems in India, Fischer MV also owns a diverse portfolio of breakthrough diagnostic solutions and AI healthcare platform. Moving into preventative healthcare for livestock and aquaculture with BAV shows its commitment to improve healthcare through greater food security.**



- Fischer MV and BAV are planning to establish a production facility in India to serve the local and Middle Eastern markets where livestock populations are top on the world's list.
- **BAV Spray Technology Vaccine (STVAC)** was developed and patented by BAV's founder, Prof. Mohd Zamri Saad, in collaboration with scientists from the Faculty of Veterinary Medicine at Universiti Putra Malaysia (UPM). In addition to STVAC, BAV has developed several other innovative solutions.
- **VIVAC aqua-feed is a *Vibrio* vaccine that provides cross-protection against a range of pathogenic *Vibrio spp.* prevalent in Asian marine fish cultures.** Administered effectively through fish feed, VIVAC addresses the challenges faced by small and medium-sized fish farmers who struggle with labour-intensive and costly injectable vaccines.
- **AQUABOOSTER is an oral feed vaccine that offers cross-protection against multiple species of pathogenic *Streptococcus spp.* and *Aeromonas spp.* prevalent in freshwater fish farming across Asia.** AQUABOOSTER has been shown to significantly increase survival rates by 60-90%.
- **SEABIOBROWN is a symbiotic feed enhancer for shrimp health, combining prebiotics and probiotics to help prevent acute hepatopancreatic necrosis disease (AHPND) and vibriosis outbreaks, which contribute to early mortality syndrome (EMS) in shrimp.** Aside from vaccines, BAV is also expanding into other animal-related products such as disinfectants, antiseptics and treatment.
- Data from Food and Agriculture Organisation (FAO) of the United States shows: Global animal vaccines market size value USD18.8 billion in 2024; Aquaculture vaccine market size is over USD 201.5 million in 2020 and estimated to grow at 4.3% CAGR to 2027 driven by increasing incidence of bacterial infections in various fish species; Global freshwater fish market is evaluated at USD149.895 billion for the year 2019 and projected to grow to USD183.544 billion by the year 2026.
- BAV's state-of-the-art facility in Malaysia, the first bacteria-based GMP-accredited facility in Southeast Asia is fully functional now to manufacture its range of vaccines to fulfil their huge annual orders pipeline. BAV is rolling out its expansion plans globally with Fischer MV, starting from India where both livestock and marine population leads the world.
- **Mr. Ravindran Govindan, Chairman & Managing Director of Fischer MV,** announces the collaboration with confidence: "This collaboration with BAV is our commitment in food security, starting from India with the 2nd largest sheep & goat population of about 223 million, and where food security is a growing issue. With Fischer MV's expertise in MedTech solutions, robust resources, and strategic network, we look forward to bring BAV's ground-breaking, cost-effective animal vaccines and products to the rest of the world to improve our food safety."



- **Ms. Noor Shazreena Ishak, CEO of BAV** is elated to partner Fischer MV: “In view of the growing demand for preventive healthcare in the animal world, we are committed to offer easy, cost-effective and, trustworthy solutions to relief the stress of our livestock and aquaculture and greatly improve the ROI of farmers. Through this collaboration with Fischer MV, we will have stronger science, tech and marketing support to meet the global demand for quality and affordable animal vaccines, and ultimately help reduce the burden of animal diseases worldwide.”
- This partnership with BAV represents a pivotal moment for Fischer MV to advance its mission to strengthen global food security and health. Fischer MV is committed to take a major step towards ensuring world's food supply remains safe and resilient, directly contributing to better healthcare and healthier lives for people everywhere.

Disclaimer:

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (formerly known as Fischer Chemic Ltd) (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", " estimates", " anticipates", " projects", " expects", " intends", " may", " will", " or " or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHER MV** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.
